"Palo Verde Cancer Specialists is dedicated to providing the most advanced and compassionate cancer care available in the Valley. Unlike many other cancer treatment centers, our centers include a comprehensive array of life-saving treatments administered by board-certified hematologists, oncologists, and radiation oncologists. Each specialist will walk you through the process, from diagnosis to treatment. Assembling all of these specialists at one center and working with such a multitude of treatment options means you can be confident that you are getting the best possible treatment plan.Cancer Treatment For The Unique YouThere are many types of cancer treatment."

During the past decade, Palo Verde Hematology Oncology conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 4 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Palo Verde Hematology Oncology" #1 sponsor was "Celgene" with 3 trials, followed by "Helsinn Therapeutics (U.S.), Inc" with 2 trials sponsored, "TetraLogic Pharmaceuticals" with 2 trials sponsored, "Celgene Corporation" with 1 trials sponsored and "Cell Genesys" with 1 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Palo Verde Hematology Oncology" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Arcus Biosciences, Inc." with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Palo Verde Hematology Oncology" are "Cancer Cachexia" (2 trials), "Colorectal Neoplasms" (2 trials), "Multiple Myeloma" (2 trials), "Non-small Cell Lung Cancer" (2 trials) and "Advanced Prostate Cancer" (1 trials). Many other conditions were trialed in "Palo Verde Hematology Oncology" in a lesser frequency.

Most popular intervention types in "Palo Verde Hematology Oncology" are "Drug" (20 trials), "Biological" (2 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Pembrolizumab" (2 trials), "5-Azacitidine" (1 trials), "Abemaciclib" (1 trials) and "Abraxane (Induction)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Palo Verde Hematology Oncology" are 19 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Palo Verde Hematology Oncology". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Palo Verde Hematology Oncology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Palo Verde Hematology Oncology, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".